PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression
Nature Medicine2016Vol. 22(11), pp. 1321–1329
Citations Over TimeTop 1% of 2016 papers
Dai Horiuchi, Roman Camarda, Alicia Y. Zhou, Christina Yau, Olga Momčilović, Sanjeev Balakrishnan, Alexandra Corella, Henok Eyob, Kai Kessenbrock, Devon A. Lawson, Lindsey A. Marsh, Brittany Anderton, Julia Rohrberg, Ratika Kunder, Alexey V. Bazarov, Paul Yaswen, Michael T. McManus, Hope S. Rugo, Zena Werb, Andrei Goga
Related Papers
- → Abstract P2-05-09: Functional mapping of the oncogenic kinome activity of triple-negative breast cancer cells(2015)
- → Faculty Opinions recommendation of Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.(2012)
- → Faculty Opinions recommendation of Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.(2012)
- → Supplementary Table 1 from Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation(2023)
- → Supplementary Table 1 from Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation(2023)